"In the US, we have long recognised that we need new ways to reach patients more directly by removing barriers in the system"
— Victor Bultó, President of Novartis US

Novartis Launches Groundbreaking Direct-to-Patient Platform

Platform Details and Pricing Strategy

Market Impact and Industry Implications

Swiss Innovation in US Healthcare

Sources & References

Novartis launches direct sales platform in US in bid to lower drug prices

SWI swissinfo.ch

Key Takeaways

Novartis is launching a direct-to-patient platform in the US market
The platform will launch on November 1, 2025
Cosentyx will be offered at a 55% discount on list price
Cosentyx is Novartis' best-selling product in the US

By The Numbers

55%

Discount on Cosentyx list price

They Said

"In the US, we have long recognised that we need new ways to reach patients more directly by removing barriers in the system"
— Victor Bultó, President of Novartis US

Filed Under